467 related articles for article (PubMed ID: 31483522)
1. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
2. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
[TBL] [Abstract][Full Text] [Related]
3. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
Dreesen E; Verstockt B; Bian S; de Bruyn M; Compernolle G; Tops S; Noman M; Van Assche G; Ferrante M; Gils A; Vermeire S
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1937-1946.e8. PubMed ID: 29704680
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.
Al-Bawardy B; Ramos GP; Willrich MAV; Jenkins SM; Park SH; Aniwan S; Schoenoff SA; Bruining DH; Papadakis KA; Raffals L; Tremaine WJ; Loftus EV
Inflamm Bowel Dis; 2019 Feb; 25(3):580-586. PubMed ID: 30165638
[TBL] [Abstract][Full Text] [Related]
5. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
6. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
Guidi L; Pugliese D; Panici Tonucci T; Bertani L; Costa F; Privitera G; Tolusso B; Di Mario C; Albano E; Tapete G; Gremese E; Papa A; Gasbarrini A; Rapaccini GL; Armuzzi A
United European Gastroenterol J; 2019 Nov; 7(9):1189-1197. PubMed ID: 31700632
[TBL] [Abstract][Full Text] [Related]
7. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
Williet N; Boschetti G; Fovet M; Di Bernado T; Claudez P; Del Tedesco E; Jarlot C; Rinaldi L; Berger A; Phelip JM; Flourie B; Nancey S; Paul S; Roblin X
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1750-1757.e3. PubMed ID: 27890854
[TBL] [Abstract][Full Text] [Related]
8. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
[TBL] [Abstract][Full Text] [Related]
9. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
Yacoub W; Williet N; Pouillon L; Di-Bernado T; De Carvalho Bittencourt M; Nancey S; Lopez A; Paul S; Zallot C; Roblin X; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2018 Apr; 47(7):906-912. PubMed ID: 29384209
[TBL] [Abstract][Full Text] [Related]
10. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
Hanžel J; Sever N; Ferkolj I; Štabuc B; Smrekar N; Kurent T; Koželj M; Novak G; Compernolle G; Tops S; Gils A; Drobne D
United European Gastroenterol J; 2019 Jul; 7(6):741-749. PubMed ID: 31316778
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.
Pouillon L; Rousseau H; Busby-Venner H; De Carvalho Bittencourt M; Choukour M; Gauchotte G; Zallot C; Danese S; Baumann C; Peyrin-Biroulet L
J Crohns Colitis; 2019 Aug; 13(8):970-975. PubMed ID: 30698684
[TBL] [Abstract][Full Text] [Related]
12. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.
Hemming-Harlo M; Merras-Salmio L; Nikkonen A; Kolho KL
Eur J Pediatr; 2024 Jan; 183(1):313-322. PubMed ID: 37878072
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.
Steenholdt C; Lorentsen RD; Petersen PN; Widigson ES; Kloft C; Klaasen RA; Brynskov J
J Gastroenterol Hepatol; 2024 Jun; 39(6):1088-1098. PubMed ID: 38380724
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
15. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
Shapina MV; Nanaeva BA
Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.
Yarur AJ; Bruss A; Naik S; Beniwal-Patel P; Fox C; Jain A; Berens B; Patel A; Ungaro R; Bahur B; Dubinsky M; Stein DJ
Dig Dis Sci; 2019 Jun; 64(6):1651-1659. PubMed ID: 30835029
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease.
Aardoom MA; Jongsma MME; de Vries A; Wolthoorn J; de Ridder L; Escher JC
J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):501-507. PubMed ID: 32639455
[TBL] [Abstract][Full Text] [Related]
18. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
19. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
20. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]